6 September 2017 - NICE has updated its 2010 guidance on the use of sorafenib tosylate (Nexavar) on the NHS for the treatment of patients with advanced hepatocellular carcinoma.

Sorafenib is now recommended as an option for treating advanced hepatocellular carcinoma only for people with Child-Pugh grade A liver impairment, only if Bayer provides sorafenib tosylate within the agreed commercial access arrangement.

The NICE Appraisal Committee concluded that sorafenib tosylate could plausibly meet the criteria to be considered a life-extending, end-of-life treatment.

Read NICE Final Appraisal Determination for sorafenib tosylate